-
Complicated urinary tract infections (cUTIs), including pyelonephritis, in adults.
-
Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).
-
Bacteraemia associated with, or suspected to be associated with, cUTIs or HAP.

ORBLICEF 2.5gm
| MRP | : |
|
| Price | : | ₹1,200.00 |
| You Save | : | ₹384.38 (24.26%) |
1 Vial(s)
Orblicef 2.5gm Injection is a combination of two medications: Cefepime and Enmetazobactam. Cefepime is an antibiotic belonging to the cephalosporin class, while Enmetazobactam enhances the antibiotic’s effectiveness by inhibiting specific enzymes that bacteria utilize for self-protection. This medication falls under the category of broad-spectrum antibiotics and is indicated for the treatment of serious infections, including complicated urinary tract infections (cUTIs), lung infections such as hospital-acquired pneumonia, and other severe infections caused by resistant bacteria.
Orblicef Injection is typically administered in hospitals by a healthcare professional via injection. As with all medications, it may lead to some side effects, including nausea, diarrhea, headache, or discomfort at the injection site. Orblicef 2.5gm Injection should be used strictly as prescribed by the physician. It may pose risks for individuals with kidney issues unless the dosage is modified. It is contraindicated for anyone with allergies to cephalosporins, penicillins, or related antibiotics. Always inform your doctor about any existing health conditions or other medications you are currently taking before commencing this treatment.